Phase 4 N=17 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Peritoneal Dialysis Complication · Hyperphosphatemia · Hypoalbuminemia
Primary: Serum Phosphate at Baseline — 7.47 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 Prophylactic Antibiotics in Admitted Cirrhotics
Cirrhosis, Liver
Primary: Infections — 2; 5 Participants
Phase 4 N=25 RIXUBIS PMS India (RIXUBIS PMS)
Hemophilia B
Primary: Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) Related to RIXUBIS — 0 Participants
Phase 4 N=17 The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown
Skin Infection
Primary: Holgers Classification of Skin Reactions at the Surgical Site Graded 0 (no Reaction) to 4 (Worse Outcome) — 1.06; 0.64; 0.81; 0.50 Grade
Phase 4 N=10 Abatacept in Juvenile Dermatomyositis
Dermatomyositis
Primary: Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by…
Phase 4 N=92 Ideal Steroids for Asthma Treatment in the PICU
Asthma Childhood
Primary: Length of Stay — 2.9; 2.9 days — p=0.632
Phase 4 N=12 Growth and Development Study of Alglucosidase Alfa
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Recumbent Height/Length of Participants in Centimeters (cm) — 80.4; 93.8; 67.7; 91.1 cm
Phase 4 N=61 Phosphate Lowering in CKD Trial
Chronic Kidney Disease · Cardiovascular Disease
Primary: Brachial Artery Flow-mediated Dilation — 3.13; 3.74; 2.73; 3.09 percent change FMD
Phase 4 N=45 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
Relapsed and/or Refractory Multiple Myeloma
Primary: Progression-Free Survival (PFS) Rate at 12 Months From the Start of Study Treatment — 50.0; 48.7; 48.9 Percentage of Participants
Phase 4 N=81 Vorapaxar on Thrombin Generation and Coagulability
Coronary Artery Disease · Peripheral Vascular Disease · Myocardial Infarction
Primary: Effects of Vorapaxar on 15 μmol/L SFLLRN (PAR-1 Activating Peptide) Induced Platelet Aggregation — 8; 5; 5; 4 Maximum aggregation (%)
Phase 4 N=93 Cardiovascular Effects of GLP-1 Receptor Activation
Obesity · PreDiabetes
Primary: Change in Flow-mediated Dilation — 0.71; 2.06; 1.24; 0.48 Percentage
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Phase 4 N=66,228 Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
Childhood Mortality
Primary: All-cause Mortality Rate in Children Aged 1-60 Months — 24.8; 26.7 deaths per 1000 person years
Phase 4 N=60 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
HIV Infections
Primary: Symptom Score — 10; 8 units on a scale — p=0.45
Phase 4 N=98 Sub-dissociative Dose Ketamine Dosing Study
Acute Pain
Primary: Change in Pain Score From Baseline to 30 Minutes Post Initiation of Drug Administration — 3.8; 3.5 score on a scale